<DOC>
	<DOCNO>NCT01526148</DOCNO>
	<brief_summary>This 4-month randomized open-label comparative safety , tolerability , effectiveness trial Lithium versus Quetiapine subject present phase Bipolar currently require medication change illness . Stratified randomization reduce bipolar type I , bipolar type II , sub-threshold imbalance across cell . The enrollment goal 60 subject , 24 month initial regulatory approval . The primary outcome difference lithium quetiapine time 'all cause ' medication discontinuation .</brief_summary>
	<brief_title>Gao Bipolar Spectrum Lithium/Quetiapine Study</brief_title>
	<detailed_description />
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Lithium Carbonate</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Able provide inform consent begin studyspecific procedure Male female patient least 18 year age Meets Diagnostic Statistical Manual IV criterion BPI , BP II , National Comorbidity SurveyR criterion subthreshold BP without symptom , need medication adjustment ( ) Willing randomize either Lithium Quetiapine If sexually active female childbearing potential , use reliable method contraception , oral contraceptive longterm injectable implantable hormonal contraceptive , doublebarrier method ( e.g . condom diaphragm , condom foam , condom sponge ) , intrauterine device , tubal ligation Women reproductive potential must negative urine pregnancy test Unwilling comply study requirement Patients severe adverse reaction Lithium Quetiapine Patients require inpatient care Drug/alcohol dependence require immediate acute detoxification Pregnancy determine serum pregnancy test breastfeed History nonresponse Lithium dose &gt; 900 mg ≥8 wks Quetiapine dose least 300 mg/d ≥ 8 week depression least 400600 mg/d ≥ 4 wks mania .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>